Patents Represented by Attorney Arnall Golden Gregory
  • Patent number: 6217894
    Abstract: An improved barrier or drug delivery system which is highly adherent to the surface to which it is applied is disclosed, along with methods for making the barrier. In the preferred embodiment, the system is compliant, in that it is capable of conforming to the three dimensional structure of a tissue surface as the tissue bends and deforms during healing processes. The barrier or drug delivery systems is formed as a polymeric coating on tissue surfaces by applied a polymerizable monomer to the surface, and then polymerizing the monomer. The polymerized compliant coating preferably is biodegradable and biocompatible, and can be designed with selected properties of compliancy and elasticity for different surgical and therapeutic applications.
    Type: Grant
    Filed: January 4, 2000
    Date of Patent: April 17, 2001
    Assignee: Focal, Inc.
    Inventors: Amapreet S. Sawhney, Michelle D. Lyman, Peter K. Jarrett, Ronald S. Rudowsky
  • Patent number: 6214387
    Abstract: Biodegradable controlled release microspheres for the prolonged administration of a local anesthetic agent, and a method for the manufacture thereof are disclosed. The microspheres are formed of a biodegradable polymer degrading significantly within a month, with at least 50% of the polymer degrading into non-toxic residues which are removed by the body within a two week period. Useful polymers include polyanhydrides, polylactic acid-glycolic acid copolymers and polyorthoesters containing a catalyst; polylactic acid-glycolic acid copolymers are preferred. Local anesthetics are incorporated into the polymer using a method that yields a uniform dispersion, preferably solvent casting. Prolonged release is obtained by incorporation of a glucocorticoid into the polymeric matrix or by co-administration of the glucocorticoid with the microspheres. The type of anesthetic and the quantity are selected based on the known pharmaceutical properties of these compounds.
    Type: Grant
    Filed: September 17, 1997
    Date of Patent: April 10, 2001
    Assignee: Children's Medical Center Corporation
    Inventors: Charles B. Berde, Robert S. Langer
  • Patent number: 6214920
    Abstract: Molding compositions including polyhydroxyalkanoates are provided. The use of polyhydroxyalkanoates as a binder in molding compositions provides improved binder removal in the finished molded product, and offers a wide range of physical properties suitable for use in a variety of processing conditions. The composition preferably includes a powdered material, such as a metal powder, ceramic powder, or blend, admixed with a polyhydroxyalkanoate binder. The compositions are useful in powder processing techniques, such as injection molding, slip casting, tape casting, or extrusion.
    Type: Grant
    Filed: June 5, 2000
    Date of Patent: April 10, 2001
    Assignee: Metabolix, Inc.
    Inventors: Edward Muller, Daniel Horowitz, Anna Egozy
  • Patent number: 6214606
    Abstract: A purified, biologically active yeast mitochondrial heat shock protein exhibiting an Mr of about 60K (hsp60) and its biologically active analogs exhibiting an Mr of 55K-65K are disclosed. Polynucleotide segments that encode hsp60 and its analogs are disclosed as are vectors containing the same, as well as transformed cells that contain the vectors. Methods of assembling non-functional protein subunits into a functional oligomeric protein complex and for converting an inactive form of a monomeric protein molecule or protein subunit molecule into an active form of the molecule are also disclosed.
    Type: Grant
    Filed: March 18, 1991
    Date of Patent: April 10, 2001
    Inventors: Arthur L. Horwich, Mingyuan Cheng, Richard Hallberg, Donald S. Reading, Alan Myers
  • Patent number: 6210884
    Abstract: Disclosed are compositions and a method for of amplifying nucleic acid sequences useful for detecting the presence of molecules of interest. The method is useful for detecting specific nucleic acids in a sample with high specificity and sensitivity. The method also has an inherently low level of background signal. A preferred form of the method consists of a DNA ligation operation, an amplification operation, and a detection operation. The DNA ligation operation circularizes a specially designed nucleic acid probe molecule. This operation is dependent on hybridization of the probe to a target sequence and forms circular probe molecules in proportion to the amount of target sequence present in a sample. The amplification operation is rolling circle replication of the circularized probe. A single round of amplification using rolling circle replication results in a large amplification of the circularized probe sequences.
    Type: Grant
    Filed: August 11, 1998
    Date of Patent: April 3, 2001
    Assignee: Yale University
    Inventor: Paul M. Lizardi
  • Patent number: 6206911
    Abstract: Radially expandable intraluminal stents (11) suitable for providing interior support within a human blood vessel are disclosed. A material (33′) used to construct the stent (11) is formed into diamond cells (35). The diamond cells (35) each have arms (37) of equal length. Diamond cells (35) are interconnected to other diamond cells (25) by legs (39, 39a) or to pairs of smaller cells (41) which have a common vertex and four arms (43) of equal length. Needle-like prongs (51, 53) are attached to the diamond cells (35) at their vertex to function as attachment means for a biological membrane (57′).
    Type: Grant
    Filed: November 2, 1998
    Date of Patent: March 27, 2001
    Inventor: Simcha Milo
  • Patent number: 6207197
    Abstract: There is provided a drug delivery composition for the controlled release of an active agent in the stomach environment over a prolonged period of time, which comprises a microsphere comprising an active ingredient in the inner core of the microsphere and (i) a rate controlling layer of a water insoluble polymer and (ii) an outer layer of a bioadhesive agent in the form of a cationic polymer.
    Type: Grant
    Filed: November 18, 1999
    Date of Patent: March 27, 2001
    Assignee: West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited
    Inventors: Lisbeth Illum, He Ping
  • Patent number: 6207749
    Abstract: Synthetic comb copolymers which elicit controlled cellular response, methods of applying these polymers to various surfaces, and methods of using the polymers for modifying biomaterial surfaces, in tissue engineering applications and as drug delivery devices are provided. The comb copolymers are comprised of hydrophobic polymer backbones and hydrophilic, non-cell binding side chains which can be end-capped with cell-signaling ligands that guide cellular response. By mixing non-cell binding combs with ligand-bearing combs, the surface concentration and spatial distribution of one or more types of ligands, including adhesion peptides and growth factors, can be tuned on a surface to achieve desired cellular response. In one embodiment, the combs are used as stabilizing agents for dispersion polymerization of latexes. The comb-stabilized latexes can be applied to substrates by standard coating operations to create a bioregulating surface, or used as drug delivery agents.
    Type: Grant
    Filed: August 8, 2000
    Date of Patent: March 27, 2001
    Assignee: Massachusetts Institute of Technology
    Inventors: Anne M. Mayes, Linda G. Griffith, Darrell J. Irvine, Pallab Banerjee, Terry D. Johnson
  • Patent number: 6207217
    Abstract: Compositions providing increased energy content of animal feed using plant crop biomass which include a polyhydroxyalkanoate have been developed. In one embodiment, the compositions can be prepared using conventional techniques for harvesting and processing plant crops into forms useful as animal feed, wherein the plant, or parts thereof, have accumulated PHA, preferably in excess of 2% by dry weight of the plant tissue. In a preferred embodiment, the PHA is accumulated in corn or an oilseed. The feed compositions can include the PHA-containing meal byproduct from corn or oilseed processing. In another embodiment, the PHA can be provided with the green tissue of plants, such as clover, alfalfa, sorghum, and silage corn.
    Type: Grant
    Filed: January 7, 1999
    Date of Patent: March 27, 2001
    Assignees: Pioneer Hi-Bred International, Inc., Metabolix, Inc.
    Inventors: Oliver P. Peoples, Court Saunders, Scott Nichols, Larry Beach
  • Patent number: 6200602
    Abstract: The invention provides a drug delivery composition for colonic delivery comprising a polar drug, an absorption promoter which (a) comprises a mixture of a fatty acid having 6 to 16 carbon atoms or a salt thereof and a dispersing agent, or (b) comprises a mixture of mono/diglycerides of medium chain fatty acids and a dispersing agent, and means adapted to release the polar drug and absorption promoter in the colon following oral administration. A preferred fatty acid is capric acid or a salt thereof. Colon specific delivery can be achieved by providing the composition in a capsule, tablet or pellet which is coated with a material which dissolves in the small intestine or is degraded by the conditions in the colon.
    Type: Grant
    Filed: March 30, 1998
    Date of Patent: March 13, 2001
    Assignee: West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited
    Inventors: Peter James Watts, Lisbeth Illum
  • Patent number: 6200751
    Abstract: The promoter of the EPCR gene has been isolated from both murine (SEQ. ID No. 1) and human (SEQ. ID No. 2) genomic libraries. The promoter includes a region (nucleotides 3130 to 3350 of SEQ. ID No. 1 which affects selective gene expression in endothelial cells), and a region (nucleotides 2270 to 2840 of SEQ. ID No. 1) which affects selective gene expression in large vessel endothelial cells, as compared to expression in all endothelial cells. The EPCR promoter contains a thrombin responsive element, CCCACCCC (SEQ. ID No. 3), (murine, nucleotides 3007 to 3014 SEQ. ID No. 1 and human, nucleotides 2722 to 2729 SEQ. ID No. 2). The EPCR also contains a serum response element (nucleotides 2990 to 3061 of SEQ. ID No. 1). The regulatory sequences present in the EPCR promoter can be used for thrombin or serum controlled recombinant gene expression specific to either all endothelial cells or primarily endothelial cells of large vessels.
    Type: Grant
    Filed: November 7, 1997
    Date of Patent: March 13, 2001
    Assignee: Oklahoma Medical Research Foundation
    Inventors: Jian-Ming Gu, Charles T. Esmon
  • Patent number: 6201065
    Abstract: Gel-forming macromers including at least four polymeric blocks, at least two of which are hydrophobic and at least one of which is hydrophilic, and including a crosslinkable group are provided. The macromers can be covalently crosslinked to form a gel on a tissue surface in vivo. The gels formed from the macromers have a combination of properties including thermosensitivity and lipophilicity, and are useful in a variety of medical applications including drug delivery and tissue coating.
    Type: Grant
    Filed: July 26, 1996
    Date of Patent: March 13, 2001
    Assignee: Focal, Inc.
    Inventors: Chandrashekhar P. Pathak, Shikha P. Barman, C. Michael Philbrook, Amarpreet S. Sawhney, Arthur J. Coury, Luis Z. Avila, Mark T. Kieras
  • Patent number: 6197346
    Abstract: Bioadhesive polymers in the form of, or as a coating on, microcapsules containing drugs or bioactive substances which may serve for therapeutic, diagnostic, or diagnostic purposes in diseases of the gastrointestinal tract, are described. The polymeric microspheres all have a bioadhesive force of at least 11 mN/cm2 (110 N/CM2). Techniques for the fabrication of bioadhesive microspheres, as well as a method for measuring bioadhesive forces between microspheres and selected segments of the gastrointestinal tract in vitro are also described. This quantitative method provides a means to establish a correlation between the chemical nature, the surface morphology and the dimensions of drug-loaded microspheres on one hand and bioadhesive forces on the other, allowing the screening of the most promising materials from a relatively large group of natural and synthetic polymers which, from theoretical consideration, should be used for making bioadhesive microspheres.
    Type: Grant
    Filed: April 24, 1992
    Date of Patent: March 6, 2001
    Assignee: Brown Universtiy Research Foundation
    Inventors: Edith Mathiowitz, Donald Chickering, Jules Serge Jacob
  • Patent number: 6197575
    Abstract: Systems including (1) a micromatrix and perfusion assembly suitable for seeding and attachment of cells within the matrix and for morphogenesis of seeded cells into complex, hierarchical tissue or organ structures, wherein the matrix includes channels or vessels through which culture medium, oxygen, or other nutrient or body fluids can be perfused while controlling gradients of nutrients and exogenous metabolites throughout the perfusion path independently of perfusion rate, and (2) sensor means for detecting changes in either cells within the matrix or in materials exposed to the cells, have been developed. Methods for making the micromatrices include micromachining, micromolding, embossing, laser drilling, and electro deposition machining. Cells can be of one or more types, either differentiated or undifferentiated.
    Type: Grant
    Filed: March 18, 1999
    Date of Patent: March 6, 2001
    Assignee: Massachusetts Institute of Technology
    Inventors: Linda G. Griffith, Steven Tannenbaum, Mark J. Powers, Karel Domansky, Charles D. Thompson
  • Patent number: 6190315
    Abstract: Methods for enhanced transdermal transport wherein the application of ultrasound is required only once for repeated or sustained transdermal extraction or delivery, over a period of time, rather than prior to each extraction or delivery. The method is applicable to analyte extraction, as well as for drug delivery. The method involves the initial application of an amount of low frequency ultrasound effective to permeabilize the skin or membrane followed by analyte extraction or drug delivery over a period of time. The initial application of ultrasound is effective to permeabilize the skin or membrane for at least about 30 minutes, preferably at least one to two hours, and more preferably up to four to ten hours. The ultrasound is preferably low frequency ultrasound, less than 2.5 MHz, more preferably less than 1 MHz.
    Type: Grant
    Filed: January 8, 1999
    Date of Patent: February 20, 2001
    Assignee: Sontra Medical, Inc.
    Inventors: Joseph Kost, Samir S. Mitragotri, Robert S. Langer
  • Patent number: 6183960
    Abstract: Disclosed are compositions and a method for of amplifying nucleic acid sequences useful for detecting the presence of molecules of interest. The method is useful for detecting specific nucleic acids in a sample with high specificity and sensitivity. The method also has an inherently low level of background signal. A preferred form of the method consists of a DNA ligation operation, an amplification operation, and a detection operation. The DNA ligation operation circularizes a specially designed nucleic acid probe molecule. This operation is dependent on hybridization of the probe to a target sequence and forms circular probe molecules in proportion to the amount of target sequence present in a sample. The amplification operation is rolling circle replication of the circularized probe. A single round of amplification using rolling circle replication results in a large amplification of the circularized probe sequences.
    Type: Grant
    Filed: August 11, 1998
    Date of Patent: February 6, 2001
    Assignee: Yale University
    Inventor: Paul M. Lizardi
  • Patent number: 6176874
    Abstract: Solid free-form fabrication (SFF) methods are used to manufacture devices for allowing tissue regeneration and for seeding and implanting cells to form organ and structural components, which can additionally provide controlled release of bioactive agents, wherein the matrix is characterized by a network of lumens functionally equivalent to the naturally occurring vasculature of the tissue formed by the implanted cells, and which can be lined with endothelial cells and coupled to blood vessels at the time of implantation to form a vascular network throughout the matrix. The SFF methods can be adapted for use with a variety of polymeric, inorganic and composite materials to create structures with defined compositions, strengths, and densities, using computer aided design (CAD). Examples of SFF methods include stereo-lithography (SLA), selective laser sintering (SLS), ballistic particle manufacturing (BPM), fusion deposition modeling (FDM), and three dimensional printing (3DP).
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 23, 2001
    Assignees: Masschusetts Institute of Technology, Children's Medical Center Corporation
    Inventors: Joseph P. Vacanti, Linda G. Cima, Michael J. Cima
  • Patent number: 6177095
    Abstract: Water-soluble macromers including at least one hydrolysable linkage formed from carbonate or dioxanone groups, at least one water-soluble polymeric block, and at least one polymerizable group, and methods of preparation and use thereof are described. The macromers are preferably polymerized using free radical initiators under the influence of long wavelength ultraviolet light or visible light excitation. Biodegradation occurs at the linkages within the extension oligomers and results in fragments which are non-toxic and easily removed from the body. The macromers can be used to encapsulate cells, deliver prophylactic, therapeutic or diagnostic agents in a controlled manner, plug leaks in tissue, prevent adhesion formation after surgical procedures, temporarily protect or separate tissue surfaces, and adhere or seal tissues together.
    Type: Grant
    Filed: January 7, 2000
    Date of Patent: January 23, 2001
    Assignee: Focal, Inc
    Inventors: Amarpreet S. Sawhney, Peter K. Jarrett, Arthur J. Coury, Ronald S. Rudowsky, Michelle D. Powell, Luis Z. Avila, David J. Enscore, Stephen D. Goodrich, William C. Nason, Fei Yao, Douglas Weaver, Shikha P. Barman
  • Patent number: 6173199
    Abstract: A catheter having a distal end portion including a sensor responsive to the presence of a magnetic field or flux of a predetermined strength is provided. Also provided is a catheter system which further includes an external magnet. The sensor in the distal end portion is selected to respond when the distal end portion of the catheter is exposed to a magnetic field, such as provided by the external magnet, sufficient to capture and maneuver the distal end of the catheter. A catheter having a distal end portion that includes a steering portion for maneuvering the distal end of the catheter during intubation of a patient is also provided. A method for intubating a patient using the catheter systems provided, including an external magnet, is also disclosed.
    Type: Grant
    Filed: May 5, 1998
    Date of Patent: January 9, 2001
    Assignee: Syncro Medical Innovations, Inc.
    Inventor: Sabry Gabriel
  • Patent number: 6165750
    Abstract: Streptavidin tetramers have at least one monomer containing an amino acid modification that produces a reduced binding affinity for biotin, a modified off-rate, a modified on-rate, or an altered binding enthalpy. Polynucleotides encoding the modified monomers are also provided. The modified streptavidin and chimeric streptavidin molecules are useful in methods of bioseparations and cell sorting, imaging, drug delivery, and diagnostics.
    Type: Grant
    Filed: March 5, 1998
    Date of Patent: December 26, 2000
    Assignee: University of Washington
    Inventor: Patrick S. Stayton